Reddy’s Laboratories announces the launch of Tobramycin Inhalation Solution, USP in the U.S. Market

June 26, 2019 Praveen Business Comments Off on Reddy’s Laboratories announces the launch of Tobramycin Inhalation Solution, USP in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).

The TOBI® (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.

Dr. Reddy’s Tobramycin Inhalation Solution, USP is available in a 300 mg/5 mL, single-dose Ampule.

 

Tobi® is a trademark of Mylan.

*IQVIA Retail and Non-Retail MAT April 2019.

RDY-0619-250

Related Articles

Business

Dr. Reddy’s Laboratories announces the launch of Fenofibrate Tablets USP, in the U.S. Market

April 30, 2020 Praveen Business Comments Off on Dr. Reddy’s Laboratories announces the launch of Fenofibrate Tablets USP, in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor® […]

Business

Dr. Reddy’s Laboratories announces the launch of Amphetamine Sulfate Tablets USP, in the U.S. Market

April 15, 2020 Praveen Business Comments Off on Dr. Reddy’s Laboratories announces the launch of Amphetamine Sulfate Tablets USP, in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Amphetamine Sulfate Tablets USP, a therapeutic equivalent generic version of […]